After implementing a workforce reduction of 1,900 US employees in January, Abbott Laboratories Inc. in recent months had re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company, to retain the Abbott name, and a research-based pharmaceuticals company, which will take a new, to-be-determined name. (See Also see "Abbott Shaves U.S. Pharma Costs With Restructuring" - Pink Sheet, 26 January, 2011..)
The research-based pharmaceuticals company will include Abbott’s current portfolio of branded marketed drugs and biologics, and is fairly dominated by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?